Ahmed Nada: Effect of Everolimus on Prognosis of Neurofibromatosis Type 1 Lesions
Ahmed Nada, Global Alliance of Young Researchers, shared on LinkedIn:
“Our Study titled:
‘Effect of Everolimus on Prognosis of Neurofibromatosis Type 1 Lesions: A Systematic Review and Meta Analysis’ has been published online.
Important Highlights:
• Explored everolimus, an mTOR inhibitor, for its effect on NF-1 lesion size via meta-analysis.
• Four phase II single arm trials with 83 patients showed no significant effect of oral everolimus on lesion size reduction.
• Safety discrepancies across studies raise concerns about everolimus’ overall safety in NF-1 patients.
• Emphasizes the necessity for more research, personalized treatments, and larger standardized trials in NF-1.
you can read the full text here.
Thanks to Global Alliance of Young Researchers, Mostafa Meshref , and Abdulqadir Nashwan for their great efforts.”
Source: Ahmed Nada/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023